Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
COMPASS Pathways (Nasdaq: CMPS) has announced an expansion of its Discovery Center through collaborations with leading scientists from UC San Diego and Medical College of Wisconsin. The new partners, Adam Halberstadt and John McCorvy, will join Jason Wallach in efforts to develop innovative psychedelic compounds targeting mental health issues. This initiative aims to address unmet medical needs and enhance the existing psilocybin therapy model. COMPASS will hold exclusive rights to the new compounds developed during this collaboration.
COMPASS Pathways (Nasdaq: CMPS) has published a paper in Frontiers in Psychiatry detailing its structured therapist training programme for psilocybin therapy. The program aims to ensure consistent quality in psychological support during COMP360 psilocybin therapy, currently in phase IIb clinical trials for treatment-resistant depression. Developed with leading experts, it includes online learning, in-person training, and ongoing mentorship. This initiative addresses previous inconsistencies in training, enhancing the safety and effectiveness of psilocybin therapy.
Summary not available.
COMPASS Pathways plc (Nasdaq: CMPS) announced participation in two upcoming investor conferences during the week of January 11, 2021. CEO George Goldsmith and President Lars Wilde will engage in a fireside chat available on demand from January 11-14 at the HC Wainwright BioConnect 2021 Conference. Additionally, they will present a business update and conduct a live fireside chat at 12:15 pm ET on January 14 during the Westwicke Healthcare Day at the ICR Conference 2021. Webcasts will be accessible through the COMPASS website's Investors section for 30 days post-event.
COMPASS Pathways (CMPS) successfully completed a $146.6 million IPO on Nasdaq, enhancing their financial position for advancing mental health innovations. They are progressing with their phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, expanding to 21 sites across 10 countries. The company strengthened its leadership team with key appointments. As of September 30, 2020, cash and equivalents reached $196.5 million, expected to fund operations into 2023. However, the net loss increased to $16.7 million for Q3 2020, compared to $5.7 million in Q3 2019.
Summary not available.
COMPASS Pathways has successfully closed its initial public offering, selling 8,625,000 American Depositary Shares (ADS) at $17.00 each, totaling gross proceeds of $146.6 million. This includes the full exercise of underwriters' options for an additional 1,125,000 ADS. The ADS began trading on the Nasdaq Global Select Market under the ticker symbol CMPS on September 18, 2020. The offering was managed by Cowen, Evercore ISI, Berenberg, Canaccord Genuity, and H.C. Wainwright & Co.
COMPASS Pathways announced the pricing of its upsized initial public offering (IPO) of 7,500,000 American Depositary Shares (ADSs) at $17.00 each, raising total gross proceeds of $127.5 million. The offering, which is managed by Cowen, Evercore ISI, and Berenberg, is expected to close around September 22, 2020, subject to customary conditions. The ADSs will begin trading on the Nasdaq Global Select Market under the ticker symbol CMPS. COMPASS focuses on innovative mental health treatments, particularly its psilocybin therapy for treatment-resistant depression.